Tirzepatide is a dual GLP-1 and GIP receptor agonist originally developed for Type 2 diabetes and now widely used for weight loss and metabolic support. It works by reducing appetite, increasing fullness, and improving insulin sensitivity.
Strong appetite suppression and weight loss support
Helps improve blood sugar control and insulin sensitivity
Supports fat metabolism and body recomposition
May reduce cravings and improve satiety
Often produces greater weight loss than Semaglutide
Nausea
Constipation or diarrhea
Fatigue
Indigestion
Abdominal discomfort
Sulfur burps
Hair loss
Pancreatitis
Gastroparesis
Gallbladder disease
Kidney complications from dehydration
Thyroid tumor risk
Hypoglycemia when combined with insulin
Use caution with:
Insulin or diabetes medications
Alcohol
Appetite suppressants
Stimulants
Large greasy meals
Avoid stacking with other GLP-1 peptides unless medically supervised.
Always disclose Tirzepatide use before surgery or anesthesia.
Do not use if:
Pregnant or breastfeeding
Personal/family history of medullary thyroid cancer
MEN 2 syndrome
Type 1 diabetes
Severe GI disease
Allergic to Tirzepatide
Subcutaneous injection
Dose once weekly
Use the same day weekly
Stay on each dose at least 4 weeks before increasing
Can be taken with or without food
2.5mg weekly
5mg weekly
Mix:
10mg vial + 1.5mL (150 units) BAC water
25 units = 2.5mg
50 units = 5mg
75 units = 7.5mg
100 units = 10mg
Mix:
30mg vial + 3mL (300 units) BAC water
25 units = 2.5mg
50 units = 5mg
75 units = 7.5mg
100 units = 10mg
125 units = 12.5mg
150 units = 15mg
Mix:
60mg vial + 2.5mL (250 units) BAC water
10 units = 2.5mg
21 units = 5mg
31 units = 7.5mg
42 units = 10mg
52 units = 12.5mg
62 units = 15mg
AOD-9604 for fat metabolism support
Tesamorelin for visceral fat reduction
Semax or Selank for mood and focus support
NAD+ or MOTS-C for energy and metabolic support
BPC-157 for GI support and recovery
CJC-1295 + Ipamorelin for muscle preservation during weight loss